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The Powerlink system for endovascular abdominal
aortic aneurysm repair: Six-year results
Grace J. Wang, MD, and Jeffrey P. Carpenter, MD, for the Endologix Investigators, Philadelphia, Pa
Objective: We compared the results of endovascular repair using the Powerlink endovascular graft with conventional open
abdominal aortic aneurysm repair through a 6-year follow-up period.
Methods: Two hundred fifty-eight patients with abdominal aortic aneurysms were prospectively enrolled in a multicenter
trial and underwent endovascular repair (N  192) or conventional open surgery (N  66). All endovascular repairs were
approached through a surgically exposed femoral artery and a percutaneously accessed femoral artery. Study endpoints
included all-cause mortality and morbidity. Follow-up imaging consisted of contrast-enhanced CT scans and plain
abdominal x-rays at 1, 6, 12 months, and annually postoperatively.
Results: Technical success was achieved in 97.9% of test patients, with four failed insertions (three early conversions
because of deployment issues, one access failure). Mean follow-up was 4.1  1.7 years (test group) and 3.1  1.9 years
(control group). Perioperative morbidity and mortality were significantly reduced in the test group compared with the
control group (P < .05). At 6 years, all-cause mortality and morbidity was no different in the Powerlink group compared
with the open repair group. There were no reported stent fractures, graft disruptions, or aneurysm ruptures. Core
laboratory-reported endoleaks included proximal or distal type I (n  1) and type I/II (n  3), with no type III or type
IV endoleaks. One explant (0.5%) was undertaken to resolve a refractory type I endoleak. A total of 37 secondary
procedures were performed in 26 patients to treat site-reported endoleak (n  26; 7 for type I and 19 for type II), graft
limb occlusion (n  7), native artery occlusion (n  3), or endograft migration (n  1). A reduction in mean aneurysm
sac diameters and volumes has been noted at every follow-up interval.
Conclusion: Consistent with other reports, perioperative morbidity and mortality were significantly reduced in the
endovascular group compared with the open repair group. Six-year follow-up of patients treated with the Powerlink
system demonstrates the continued safety and efficacy of its treatment of abdominal aortic aneurysm. ( J Vasc Surg 2008;
48:535-45.)The Powerlink device is a unibody bifurcated endo-
vascular graft utilized for repair of abdominal aortic
aneurysms. Delivery is achieved through one surgically
exposed femoral artery. The safety and efficacy of this
device at early and intermediate time points have previ-
ously been reported.1,2 We now report our experience
with this device over a long-term follow-up interval.
METHODS
Trial design. A prospective nonrandomized concur-
rently controlled trial of the safety and efficacy of the
Endologix Powerlink bifurcated system was conducted at
15 centers according to US Food and Drug Administration
guidelines. The Powerlink trial enrolled patients between
July 18, 2000 and March 31, 2003 and followed them over
a 72-month period. Mean follow-up was 4.1  1.7 years
(test group) and 3.1  1.9 years (control group). Compar-
isons were made between the endovascular and open AAA
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as well as morbidity defined as a major adverse event.
Device. The Powerlink system is a unibody bifurcated
self-expanding fully stented endovascular graft. The en-
doskeleton is a continuous cobalt-chromium wire woven
into a double spine without sutures or welds. The endoskel-
eton is covered with graft material made of expanded
polytetrafluoroethylene (ePTFE). During the trial, the de-
vice was supplied in two neck diameters (25 mm, 28 mm)
and two lengths (135 mm, 155 mm), although other sizes
are currently commercially available. The limbs of the bi-
furcated stent graft are 16 mm in diameter. The delivery
sheath has a 21F outer diameter and a tapered tip. Both
proximal and distal extension cuffs were available with
diameters of 16, 20, 25, and 28 mm.
Patient selection. Patients with nonruptured infrare-
nal aortoiliac aneurysms were eligible for enrollment. There
were 471 patients screened, out of which 258 were enrolled
in the study (192 test, 66 controls). All patients underwent
CT angiography with three-dimensional reconstruction to
determine anatomic suitability for enrollment. Scans were
analyzed by the core laboratory (M2S, West Lebanon,
NH). Control and test patients met the same inclusion and
exclusion criteria with additional vascular anatomic criteria
required for Powerlink test patients. Eligibility for endovas-
cular repair was dependent on specific anatomic criteria felt
to be met by the operating surgeon (Table I, online only).
An infrarenal aortic clamp site was required in the open
repair group.
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measurements of aneurysm neck diameter and distance
from lowest renal artery to aortic bifurcation and hypogas-
tric arteries were performed to determine the appropriate
diameter and length of the endograft. The graft diameter
was determined by oversizing the graft 10% to 20% with
respect to measured neck diameter. Graft length was cho-
sen so as to preserve at least one hypogastric artery. Aneu-
rysm volume was calculated according to M2S protocol.
Using axial slices, the first slice below the lowest renal
artery, and the last slice above the origin of the right
internal iliac artery were marked as the proximal and distal
extent of volume calculation. The Powerlink may be de-
ployed at the level of the renal arteries or seated on the
aortic bifurcation (anatomic fixation). The latter method
most often requires the placement of a proximal aortic cuff
in order to achieve a proximal infrarenal seal. Investigators
were allowed to deploy the graft in either manner.
Follow-up evaluation. Abdominal four-view x-ray
studies (anteroposterior, lateral, left and right anterior
oblique) were performed at device implantation as well as
prior to hospital discharge. Physical examination, x-ray and
computed tomography (CT) angiography were performed
at 1, 6, 12 months and annually thereafter. Graft integrity,
migration, wire fracture, presence of endoleak, and aneu-
rysm size were evaluated. These studies were evaluated by
each local site and independently by the central core labo-
ratory.
Statistical analysis. Baseline continuous variables
were compared with the Wilcoxon rank sum test and cate-
gorical variables were compared with the Fisher exact test.
Kaplan-Meier survival estimates were used to analyze rates
of mortality and major adverse events through the 6-year
follow-up period. Groups were compared using the log
rank statistic. Endoleak and aneurysm size data are pre-
sented descriptively. Changes in aneurysm diameter or
volume over time were analyzed with a paired t test. Early
and late major adverse events are presented descriptively.
Proportions of patients with events are compared between
groups using Fisher exact test. Statistical significance is
considered for P values less than .05. All statistical analyses
were performed using SAS software version 8.2 (SAS Insti-
tute, Cary, NC).
RESULTS
Patients and procedures. The Powerlink trial en-
rolled 258 patients (192 test, 66 control). Patient and
aneurysm characteristics are shown in Table II. Test pa-
tients were significantly older than patients in the control
group, but did not differ significantly with respect to gen-
der distribution or medical comorbidities. The aneurysms
in the test group were significantly smaller than those in the
control group (51.0 6.6 vs 58.0 11.6mm, P .0001).
Renal to bifurcation length was shorter in the test group
compared with the control group (113.3  17.1 vs 122.8
 24.8 mm, P  .0009). Proximal neck diameter was
smaller (22.4  2.3 vs 26.0  4.7 mm, P  .0001) andneck length was longer 29.3  11.3 vs 18.4  19.7, P 
.0001) in the test group compared with the control group.
Technical success was achieved in 188 patients in the
test group (97.9%). Endovascular repairs were performed
with the patient under general anesthesia (n 129, 67.2%),
regional anesthesia (22, 11.5%), or local anesthesia (41,
21.4%).
The devices used are listed in Table III, online only.
Proximal cuffs (n  89, all 28 mm) were required in 79
patients (42%). Distal extensions (n  29) were used in 25
patients (13.3%). Cuffs were placed intraoperatively to
obtain proximal seal in 55 patients (62 cuffs). An additional
24 patients received 27 cuffs to accommodate a wide range
of patient anatomic features in an attempt to reduce the
incidence of endoleaks.
Mean blood loss and operative time were significantly
less in the Powerlink group compared with the control
group (341 mL vs 1583 mL, P  .0001; 136 minutes vs
222 minutes, P  .0001). Mean hospital length of stay as
well as days in intensive care unit (ICU) were significantly
shorter in the test group compared with the control group
(3.3 days vs 9.5 days, P  .0001), and (0.78 days vs 4.1
days, P  .0001).
There were three intraoperative conversions to open
repair, all resulting from failed device deployment. In one
patient, early in the study, a delivery catheter limb sheath
problem prevented device deployment and necessitated
open conversion. This catheter problemwas rectified with a
minor change to the delivery catheter design and was not
subsequently observed. Another conversion was done in a
patient who demonstrated bleeding from the left external
iliac artery after deployment of the device. Upon opening, a
tear in the external iliac artery remote from the device was
noted, which was attributed to injury from a catheter or
wire. The remaining conversion was performed because of
premature deployment of the ipsilateral limb before posi-
tioning within the iliac artery, attributable to user inexpe-
rience. There was also one access failure secondary to iliac
disease on the cutdown side that prevented advancement of
the device into the aorta. This patient later underwent
placement of a commercially available device. There was
one explant at 13 months with conversion to open repair to
attempt to resolve a refractory type I endoleak.
Perioperative morbidity/mortality. The overall in-
cidence of serious adverse events was significantly reduced
in the Powerlink group compared with the control group
(25% vs 42%, P  .0075). There were significantly less
cardiac (P  .0375), gastrointestinal (P  .0199), infec-
tious (P .0042), pulmonary (P .0002), and renal (P
.0042) complications in the Powerlink group compared
with the control group at 30 days. Results summarized in
Table IV.
All-cause mortality was decreased in the Powerlink
group (1.0% vs 6.1%, P .0389). There were two deaths in
the test group. One patient developed internal bleeding
and suffered a myocardial infarction and cardiac arrest on
postoperative day one. An autopsy was declined by the
family and the etiology of the bleeding was thus not con-
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Characteristic Powerlink (N  192) Control (N  66) P-value
Male 170 (88%) 57 (86%) .6627
Female 22 (11%) 9 (14%) .6627
Average age 73 (52–88) 69 (56–83) .0008
Coronary artery disease 88 (46%) 39 (59%) .0657
Congestive heart failure 13 (7%) 2 (3.0%) .3675
Arrhythmia 31 (16%) 5 (7.6%) .1002
Valvular heart disease 7 (3.7%) 5 (7.6%) .1911
Recent (6 mo.) MI 4 (2.1%) 3 (4.6%) .3767
Prior (6 mo.) MI 47 (24%) 19 (28.8%) .5149
Angina 25 (13%) 8 (12%) 1.0000
Prior CABG 54 (28%) 20 (30%) .3675
Prior PTCA 25 (13%) 12 (18%) .3127
Valve replacement 5 (2.6%) 1 (1.5%) 1.0000
Pulmonary disease 61 (31.8%) 16 (24.2%) .2779
Diabetes mellitus 25 (13.1%) 12 (18.2%) .3142
Hypertension 122 (64%) 46 (70%) .4541
Smoking history 159 (82.8%) 57 (86%) .5667
Peripheral vascular disease 32 (17%) 10 (15%) .8488
Cerebrovascular disease 38 (19.8%) 10 (15%) .4668
Liver disease 8 (4.2%) 1 (1.5%) .4549
Prior abdominal surgery 91 (47.4%) 25 (37.8%) .1987
Characteristic
Powerlink mean (SD)
N Median (Min, Max)
Control mean (SD)
N Median (Min, Max) P-value
Distal neck diameter (mm) 22.0 (6.3) 173a 29.5 (20.4) 46a .0008
22.0 (0.0, 48.0) 25.2 (0.0, 146.0)
Distal non-aneurysmal Right iliac diameter (mm) 12.3 (2.3) 186b 19.1 (25.7) 50b .0012
12.0 (8.0, 25.0) 13.1 (1.4, 169.4)
Distal non-aneurysmal Left Iliac diameter (mm) 12.1 (1.8) 184c 16.2 (14.3) 49c .0001
12.0 (8.0, 18.0) 13.8 (1.7, 105.0)
Distal non-aneurysmal Proximal neck diameter (mm) 23.5 (2.8) 184d 27.4 (4.7) 51d .0001
24.0 (17.0, 42.0) 27.0 (18.0, 40.0)
Left distal seal zone (mm) 45.5 (19.0) 182e 38.8 (23.7) 44e .0866
45.0 (0.0, 100.0) 39.6 (0.0, 75.0)
Renal to bifurcation length (mm) 113.3 (17.1) 185f 122.8 (24.8) 47f .0009
110.0 (55.0, 198.0) 122.0 (35.0, 180.0)
Maximum aneurysm Diameter (mm) 51.0 (6.6) 188g 58.0 (11.6) 58g .0001
50.0 (40.0, 74.0) 55.0 (37.0, 98.0)
Proximal seal zone length (mm) 29.3 (11.3) 184h 18.4 (19.7) 49h .0001
27.0 (7.9, 70.0) 13.9 (0.0, 127.0)
Proximal non-aneurysmal Left iliac diameter (mm) 12.4 (1.9) 183i 15.7 (7.5) 50i .0002
12.0 (8.5, 18.0) 14.0 (5.5, 52.0)
Proximal non-aneurysmal Right iliac diameter (mm) 12.7 (2.4) 182j 15.9 (5.8) 51j .0002
12.1 (8.0, 25.0) 14.0 (5.5, 37.0)
Non-aneurysmal proximal Neck diameter (mm) 22.4 (2.3) 188k 26.0 (4.7) 55k .0001
22.0 (18.0, 26.0) 25.5 (17.1, 40.0)
Right distal seal zone Length (mm) 49.1 (36.5) 181l 38.6 (34.7) 42l .0011
45.4 (0.0, 425.0) 30.0 (0.0, 190.0)
aThere were 19 Powerlink and 20 control patients without this measurement.
bThere were 6 were Powerlink and 16 control patients without this measurement.
cThere were 8 were Powerlink and 17 control patients without this measurement.
dThere were 8 were Powerlink and 15 control patients without this measurement.
eThere were 10 were Powerlink and 22 control patients without this measurement.
fThere were 7 were Powerlink and 19 control patients without this measurement.
gThere were 4 were Powerlink and 8 control patients without this measurement.
hThere were 8 were Powerlink and 17 control patients without this measurement.
iThere were 9 were Powerlink and 16 control patients without this measurement.
jThere were 10 were Powerlink and 15 control patients without this measurement.
kThere were 4 were Powerlink and 11 control patients without this measurement.
lThere were 11 were Powerlink and 24 control patients without this measurement.
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during an emergency thoracic stent graft procedure nine
days after the index procedure. There were four deaths in
the control group. One died of hemorrhagic shock, one
died of massive pulmonary embolism, and two patients
developed multisystem organ failure 2 to 3 weeks postop-
eratively.
Late morbidity and mortality. Patients were fol-
lowed for a mean of 49months (median, 53months; range,
0.03-81 months). Follow-up data are summarized in Table
V, online only. There was no statistically significant differ-
ence in all-cause mortality between the test and control
groups (21.9% vs 19.7%, P .8618), see Fig 1; data in
Table IX, online only. There were no aneurysm ruptures
and only one late conversion to open repair in the test
group. This patient initially underwent placement of a
bifurcated device and a proximal cuff. A type I endoleak was
detected at 1 month, which was initially managed conser-
vatively, then intervened upon at 13 months. The surgeon
placed two infrarenal cuffs as well as a suprarenal cuff to
treat what appeared to be caudal cuff migration. Ballooning
Table IV. Comparison of perioperative (within 30 days) c
Powerlink and control groups marked in bold.)
Serious adverse event/complication Power
Patients experiencing at least one serious AE 47/
Access failure 1/
Anemia 1/
Bleeding 4/
Cardiac disorders 16/
Coagulation 1/
Conversion 3/
Death 2/
Delivery failure 1/
Device kink 0/
Endoleak 4/
Gastrointestinal or bowel disorders 4/
Graft occlusion 1/
Graft thrombosis 0/
Hepatobiliary disorders 1/
Infections and infestations 2/
Metabolic/nutritional 1/
Multi-organ failure 0/
Musculo/skeletal 1/
Neoplasms 5/
Neurological disorders 2/
Otherb 6/
Pain 4/
Pulmonary 5/
Renal disorders 2/
Respiratory 0/
Sepsis 0/
Supplemental procedure 5/
Thrombocytopenia 0/
Vascular disorders 19/
Wound 1/
aAdding the sub groups will not necessary result in the group total because
bTest: (1) Right leg weakness, (1) Pulseless right lower extremity, (1) Decub
injury, (1) Ruptured tendon (hand) (two patients had two events each). Co
Colocutaneous Fistula, (1) Leukocytosis, (1) Fever (origin unknown).in the region of the four overlapped cuffs resulted in aorticrupture and immediate surgical conversion, although the
patient expired from hemorrhage. There was no difference
in freedom from abdominal aortic aneurysm (AAA) mor-
Fig 1. The Kaplan-Meier survival curves for the Powerlink and
control groups are presented in the figure below. The log-rank test
was not statistically significant with P  .5065. The observed
survival rates and 95% confidence limits of the rates are presented in
Table IX.
lications in test and control groups. (P  .05 between
n/N (%) Controla n/N (%) P value
24.48) 28/66 (42.42) .0075
0.52) — —
0.52) 2/66 (3.03) .1618
2.08) 4/66 (6.06) .2091
8.33) 12/66 (18.18) .0375
0.52) 0/66 (0.00) 1.0000
1.56) — —
1.04) 4/66 (6.06) .0389
0.52) 0/66 (0.00) 1.0000
0.52) — —
2.08) — —
2.08) 6/66 (9.09) .0199
0.52) 1/66 (1.52) .4469
0.00) 1/66 (1.52) .2558
0.52) 2/66 (3.03) .1618
1.04) 6/66 (9.09) .0042
0.52) 1/66 (1.52) .4469
0.00) 1/66 (1.52) .2558
0.52) 0/66 (0.00) 1.0000
2.60) 2/66 (3.03) 1.0000
1.04) 1/66 (1.52) 1.0000
3.13) 6/66 (9.09) .0821
2.08) 0/66 (0.00) .5750
2.60) 11/66 (16.67) .0002
1.04) 6/66 (7.58) .0042
0.00) 1/66 (1.52) .2558
0.00) 2/66 (3.03) .0647
2.08) 0/66 (0.00) .3328
0.00) 1/66 (1.52) .2558
9.90) 8/66 (12.12) .6428
0.52) 2/66 (3.03) .1618
patients may experience more than one adverse event.
lcer, (2) Delirium, (1) Cold Right lower extremity, (1) Right femoral nerve
(1) Creatinine increase, (1) Retrograde ejaculation, (1) Hypovolemia, (1)omp
linka
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itus Utality between the two groups (P  .1001), see Fig 2; data
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deaths in the control group beyond 6 months and none in
the test group beyond 13 months. Freedom from AAA-
related mortality in the test group was 97.9%. Freedom
from device-related re-hospitalization at 60 months was
83.1%, see Fig 3; data in Table XI, online only. There was
no difference in freedom from major adverse events be-
tween the test and control groups (P  .5251), see Fig 4;
data in Table XII, online only.
At the 72-month follow-up period, there was a 14.3%
endoleak rate (see Fig 5; data in Table XIII, online only,
and Table VI). There were no type III or IV endoleaks and
the majority of endoleaks were type II. Within 30 days, the
rate of secondary procedures was 3.1% (6 of 192 test
patients), whereas after 30 days, the need for secondary
procedures was 10.9% (21 of 192 test patients). Thirty-
seven secondary procedures were required in 26 patients;
one patient had a secondary procedure peri-operatively
followed by another secondary procedure after 30 days.
The majority of procedures were performed to treat en-
doleak (70.3%). There were seven secondary procedures
performed in six patients to treat type I endoleak and 19
procedures performed in 13 patients to treat type II en-
Fig 2. Kaplan-Meier AAA-related survival curves for Powerlink
and control groups through 72 months.
Fig 3. Kaplan-Meier curve of freedom from device-related hospi-
talization in Powerlink group.doleak. All type I endoleaks were addressed with additionalcuff placement or balloon angioplasty while the majority of
type II endoleaks were treated with embolization (89.5%).
The range of time to intervention for treatment of en-
doleaks was broad (2-2081 days), but a greater proportion
of patients were treated more than 2 years postoperatively
(63.2%).
Graft limb stenosis/occlusion was an infrequent com-
plication, occurring in six patients (6/384 limbs, 1.6%).
The range of presentation was 26 to 480 days with the
majority presenting within two months postoperatively.
Four of the patients exhibited narrowing without occlusion
and were successfully treated with angioplasty and stenting.
Two of the six patients presented with graft limb occlusion
which required a combination of thrombolysis or throm-
bectomy in addition to angioplasty and stenting to restore
luminal flow. In defining anatomical predictors for graft
stenosis or occlusion, there was no detectable correlation
between tortuosity of iliacs and graft limb occlusion, but
2/6 patients demonstrated severe atherosclerotic narrow-
ing of their iliacs, and 3/6 patients exhibited iliac diameters
Fig 4. Kaplan-Meier curve of freedom from major adverse events
through 72months in Powerlink and control groups. The log-rank
test of the difference in freedom from major adverse event curves
between the two treatment groups was not statistically significant
(P .5251).
Fig 5. Kaplan Meier analysis of freedom from endoleak through
72 months. The curve terminates at 72 months with detection of
last endoleak.of 11.0 mm.
11
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aneurysm from percutaneous access, which was detected 1
month postoperatively and was treated with thrombin in-
jection with resolution documented 2 days later.
The overall major adverse event rate was 41.2% for test
patients and 36.4% for controls (P  .5609). The overall
serious adverse event rate was 61.5% for test patients and
68.2% for controls (P  .3761). While the percentages of
adverse events seem high, the various causes of morbidity
Table VI. Detected endoleaks, subdivided by type, over t
Endoleak
1 mo
N  123
6 mo
N 119
12 mo
N 147
None 86 (77.48) 88 (87.13) 112 (86.15) 1
All flow 25 (22.32) 13 (12.87) 18 (13.85)
Type I 1 (0.89) 0 (0.00) 0 (0.00)
Type I and II 2 (1.79) 0 (0.00) 1 (0.77)
Type II 20 (17.85) 13 (12.87) 15 (11.54)
Type III 0 (0.00) 0 (0.00) 0 (0.00)
Type IV 0 (0.00) 0 (0.00) 0 (0.00)
Indeterminate 2 (1.79) 0 (0.00) 2 (1.54)
Total evaluated 111 101 130
Table VII. Serious adverse events (SAE) following Power
SAE
31 d - 6 mo
(N  190)
6-12 mo
(N  180)
12
(N
Patients experiencing at
least one serious AE 37 (19) 24 (13) 49
Anemia 0 (0.0) 0 (0.0) 0
Bleeding 4 (2.1) 0 (0.0) 1
Cardiac disorders 8 (4.2) 6 (3.3) 14
Coagulation 0 (0.0) 0 (0.0) 0
Conversion 0 (0.0) 1 (0.6) 0
Death 6 (3.2) 5 (2.8) 8
Device migration 1 (0.5) 0 (0.0) 0
Endoleak 3 (1.6) 2 (1.1) 3
Eye disorder 0 (0.0) 0 (0.0) 0
GI or bowel disorders 3 (1.6) 0 (0.0) 3
Graft occlusion 1 (0.5) 1 (0.6) 0
Hepatobiliary 0 (0.0) 0 (0.0) 1
Infections and infestations 4 (2.1) 5 (2.8) 5
Metabolic/nutritional 0 (0.0) 0 (0.0) 0
Multi-organ failure 0 (0.0) 0 (0.0) 2
Musculoskeletal 1 (0.5) 1 (0.6) 5
Neoplasms 6 (3.2) 5 (2.8) 6
Neurological disorders 4 (2.1) 2 (1.1) 3
Other 6 (3.2) 4 (2.2) 8
Pain 1 (0.5) 0 (0.0) 5
Pulmonary 3 (1.6) 2 (1.1) 2
Renal disorders 2 (1.1) 1 (0.6) 1
Respiratory 0 (0.0) 0 (0.0) 0
Sepsis 1 (0.5) 2 (1.1) 0
Supplemental procedure 6 (3.2) 4 (2.2) 4
Urinary 1 (0.5) 0 (0.0) 1
Vascular disorders 5 (2.6) 6 (3.3) 5
Wound 0 (0.0) 0 (0.0) 1
SAEs are defined as events that result in death, are life-threatening, permane
cancer or overdose.
aadding the sub groups will not necessary result in the group total becausewere included for completeness sake, and are a reflection ofthe sick vasculopath population. The more relevant device-
related adverse event rate was 13.8%. Results are summa-
rized in Tables VII and VIII. There were no significant
differences between test and control groups with regard to
the late incidence of myocardial infarction, renal failure,
and respiratory failure, and pulmonary, gastrointestinal,
vascular, or bleeding complications. There was no statisti-
cally significant difference in all-cause mortality between
the test and control groups (21.9% vs 19.7%, P  .8618).
Core Lab)
mo
142
36 mo
N  130
48 mo
N 119
60 mo
N  90
72 mo
N  35
9.56) 95 (92.23) 85 (89.47) 64 (86.49) 24 (85.71)
0.43) 8 (7.78) 10 (10.75) 10 (13.51) 4 (14.29)
.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
.70) 7 (6.80) 8 (8.60) 8 (10.81) 2 (7.14)
.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
.74) 1 (0.97) 2 (2.15) 2 (2.70) 2 (7.14)
5 103 95 74 28
implant through 72 months (n [%])a
o
2)
24-36 mo
(N  158)
36-48 mo
(N  145)
48-60 mo
(N  130)
60-72 mo
(N  118)
) 32 (20) 40 (28) 31 (24) 12 (10)
) 1 (0.6) 0 (0.0) 1 (0.8) 1 (0.8)
) 1 (0.6) 0 (0.0) 2 (1.5) 1 (0.8)
) 8 (5.1) 15 (10) 6 (4.6) 0 (0.0)
) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 5 (3.2) 7 (4.8) 6 (4.6) 3 (2.5)
) 0 (0.0) 2 (1.4) 0 (0.0) 0 (0.0)
) 2 (1.3) 2 (1.4) 0 (0.0) 0 (0.0)
) 0 (0.00) 1 (0.7) 0 (0.0) 0 (0.0)
) 5 (3.2) 4 (2.8) 3 (2.3) 2 (1.7)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (0.6) 1 (0.7) 1 (0.8) 0 (0.0)
) 4 (2.5) 3 (2.1) 5 (1.5) 2 (1.7)
) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 1 (0.6) 1 (0.7) 4 (3.1) 2 (1.7)
) 4 (2.5) 6 (4.1) 2 (1.5) 0 (0.0)
) 1 (0.6) 4 (2.8) 4 (3.1) 0 (0.0)
) 8 (5.1) 4 (2.8) 4 (3.1) 1 (0.8)
) 4 (2.5) 1 (0.7) 2 (1.5) 0 (0.0)
) 8 (5.1) 5 (3.5) 5 (3.9) 1 (0.8)
) 1 (0.6) 1 (0.7) 0 (0.0) 1 (0.8)
) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
) 1 (0.6) 0 (0.0) 1 (0.8) 0 (0.0)
) 3 (1.9) 1 (0.7) 3 (2.3) 1 (0.8)
) 1 (0.6) 0 (0.0) 2 (1.5) 0 (0.0)
) 4 (2.5) 8 (5.5) 4 (3.1) 2 (1.7)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
r severely disabling, require or prolong hospitalization, congenital anomaly,
patients may experience more than one adverse event.ime (
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Volume 48, Number 3 Wang and Carpenter 541cause of death in the test group (28.6%) as well as the
control group (46.2%) followed by cardiac events (21.4%
and 23.1%, respectively). Graft migration was observed in
4.3% of patients over the 72-month period, but only one
had clinical sequelae with a secondary procedure (an addi-
tional cuff) required. Review of the operative notes revealed
that all cases of migration occurred in patients for whom
the Powerlink device was implanted at the level of the renal
arteries rather than seated on the aortic bifurcation. There
have been no stent fractures or ePTFE fabric defects
through 6 years.
Sac dynamics after Powerlink.
Aneurysm diameter and volume before and after
EVAR. Preoperative mean AAA diameter in the Power-
link group was 51 mm (range 40-74 mm; P  .0001.
Significant mean diameter reduction was observed at each
Table VIII. Major adverse events following Powerlink im
Major adverse
event/complication
30 d
N  192
30 d 12 mo
N  190
1 to 
N  1
Patients experiencing at
least one major adverse
event 12 (6.3) 35 (18) 23 (13
AAA rupture 0 (0.0) 0 (0.0) 0 (0.
Coronary intervention 0 (0.0) 3 (1.6) 5 (2.
Deathf 2 (1.0) 11 (5.8) 9 (5.
Myocardial infarction 2 (1.0) 3 (1.6) 5 (2.
Renal failure 2 (1.0) 4 (2.1) 0 (0.
Respiratory failure 2 (1.0) 2 (1.1)a 0 (0.
Secondary procedure 6 (3.1) 14 (7.4) b 5 (2.
Stroke 0 (0.0) 3 (1.6) 2 (1.
Transient ischemic attack 0 (0.0) 2 (1.1) 2 (1.
Conversion to open repair 3 (1.6) 1 (0.5) 0 (0.
aPowerlink patient 202-01 had two episodes of respiratory failure in this tim
bPowerlink patient 213-05 had two secondary procedures in this time perio
cPowerlink patient 210-08 had two secondary procedures in this time perio
dPowerlink patient 203-07 had two secondary procedures in this time perio
ePowerlink patient 206-04 had two secondary procedures in this time perio
fTwo (2) more deaths reported in the test cohort after 72-month time peri
Fig 6. A, Aneurysm sac diameter reduction over time
B, Aneurysm sac volume reduction over time in Powerlifollow-up interval starting at 6 months. At 6 months, themean AAA diameter was 48.2 mm and at 72 months, the
mean AAA diameter was 39.4 mm (Fig 6, A). By 72
months, 82.7% of patients exhibited a decrease in aneurysm
diameter 5 mm. In contrast, 10.3% (3/29) patients ex-
hibited an increase in sac diameter of 5mm. All sac
expansion patients had type II endoleaks documented on
CT scan, the majority of which were successfully embolized
(67%), and one of which is being managed conservatively.
Preoperative mean AAA volume was 135.4 mL (range
71-271 mL). Significant reduction in AAA volume was
noted at each follow-up interval starting at 6 months (131
mL; P  .0023), which persisted through a mean of 72
months (118 mL; P  .006). By 72 months, 78.6% of
patients exhibited a 5% or greater decrease in aneurysm
volume (Fig 6, B). Conversely, aneurysm volume increase
by 5% was noted in 17.2% (5/29) patients.
There was one reported instance of endotension in a
t through 6 years (n [%])
2 to 3 y
N  158
3 to  4 y
N  145
4 to  5 y
N  130
5 to  6 y
N  118
14 (8.9) 20 (14) 12 (9.2) 5 (4.2)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
3 (1.9) 11 (7.6) 4 (3.1) 0 (0.0)
7 (4.4) 5 (3.4) 7 (5.4) 3 (2.5)
2 (1.3) 5 (3.4) 0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
4 (2.5)d 2 (1.4) 2 (1.5)e 1 (0.8)
0 (0.0) 2 (1.4) 2 (1.5) 0 (0.0)
0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
iod.
werlink group. Error bars represent standard deviation.
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cessfully treated with sac aspiration of serous fluid and
filling of the sac with glue with subsequent regression of
aneurysm.
Sac straightening after Powerlink. Straightening of
the aortic sac was noted in 82.8% (n  53/64) of patients.
Straightening of more than 10 degrees was exhibited in
39.0% (n  25/64) of patients. Only 17.2% (n  11/64)
of patients exhibited no change or had a slight decrease in
sac angle (aorta becoming more angulated). The mean
distance between the distal renal and bifurcation increased
over time by 3.6% (Fig 7).
Explants. A total of three Powerlink devices (1.6%)
have been explanted to date; however, only one explant was
device-related. This patient was converted to open repair
13 months postoperatively due to a refractory type I en-
doleak. Two other explants were retrieved at autopsy fol-
lowing patient deaths from cancer and multiple organ
failure at 18 and 24 months postprocedure, respectively. In
each explant, there was no evidence of stent fracture or
corrosion or fabric erosions. Moreover, the degree of de-
vice wear was consistent with that observed in preclinical in
vitro durability testing.
DISCUSSION
A controlled clinical trial was conducted to evaluate the
safety and efficacy of using the Powerlink device to treat
abdominal aortic aneurysms. The Powerlink group exhib-
ited significantly less perioperative adverse events compared
with the control cohort. Long-term follow-up of the test
group did not reveal an increase in mortality rate compared
Fig 7. Aneurysm sac straightening over time. The MM
between 1 month and 3 years.with the control group, thus establishing the noninferiorityof using the Powerlink device in repairing AAA over a
6-year follow-up period.
The Powerlink system is unique among endovascular
aneurysm repair (EVAR) devices in that it only requires one
surgically exposed femoral artery for deployment. The con-
tralateral 9F sheath is placed percutaneously. This enables it
to be used in patients with one small or diseased iliac system.
Anatomic guidelines grading severity of iliac disease have been
provided by the Society forVascular Surgery (SVS)/American
Association for Vascular Surgery (AAVS).3 Severe iliac dis-
ease has been defined by: 50% calcification of vessel,
diameter 7 mm, stenotic diameter 7 mm for 3 cm in
length, more than one focal stenosis 7 mm in diameter,
tortuosity index 1.6, and iliac angle 90 degrees. These
criteria have been proposed to help stratify patients at risk
for access failure or endograft limb obstruction. The Pow-
erlink device thus helps to broaden the population of
patients that can be treated endovascularly.
Many of the Powerlink procedures were performed
under local or regional anesthesia; limiting open surgical
exposure of the femoral artery to one side likely facilitated
this. The avoidance of having to cannulate the contralateral
limb separately also simplifies deployment compared with
modular bifurcated systems.
Deployment of the device on top of the aortic bifurca-
tion allows for fixation of the device separate from the
infrarenal and iliac seal zones. While attention chiefly has
been directed towards proximal endograft fixation using a
variety of fixation mechanisms, including suprarenal fixa-
tion, radial force, penetrating hooks and barbs, device
migration continues to be an issue. The combination of
constructions demonstrate a 22.6° sac angle reductionS reradial forces at the proximal and distal fixation sites in
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tion allow for positional stability secondary to frictional
forces.4 Graft migration was observed in 4.2% of patients
over the 72-month period, but only one secondary proce-
dure (an additional cuff) was required. The long graft body
design enables placement of the graft on the aortic bifurca-
tion, making migration unlikely. Review of the operative
notes from the cases of migration revealed that these were
all cases in which the Powerlink was placed at the renal
arteries rather than on the aortic bifurcation. It is clear that
use of anatomic fixation by seating the graft on the aortic
bifurcation is the preferred embodiment of the device to
prevent migration.
The rate of secondary procedures consisting of addi-
tional cuff placement and balloon angioplasty to treat type
I endoleak, embolization of type II endoleaks, and reinter-
vention for graft limb stenosis/occlusion was 13.8%. These
results are comparable to those in other series employing
other commercially available devices.5,6,7 The use of ad-
junctive cuffs was common with the Powerlink device.
Forty-one percent (79 out of 192 subjects) had a total of 89
cuffs placed. Placement of the main body on the aortic
bifurcation leads to planned placement of a proximal cuff to
achieve a proximal seal. The long body of the device (80 or
100 mm) and 75 mm cuffs permit long lengths of overlap,
which allow accommodation for a wide range of patient
anatomy. Use of a cuff converts the Powerlink from a
unibody graft to a modular-type graft. Despite this, no type
III endoleaks were observed.
Perioperative comparison of adverse events between
Powerlink and control groups mirrored that of other con-
trolled trials of EVAR vs open AAA repair with a significant
reduction in ICU use, hospital length of stay, blood loss,
and operative time. While the absolute percentages of
overall serious adverse events (61.5%) and major adverse
events (41.2%) seem high, readers should note the inclu-
sion of various events, which were not included in prior
studies,8,9 including discovery of neoplasms, metabolic/
nutritional disorders, musculoskeletal symptoms, anemia,
and pain. The relatively longer-term follow-up also ac-
counts for the greater inclusion of adverse events, ie, myo-
cardial infarction, vascular events, neurologic events, and
renal disorders occurring in the vasculopath population.
The overall adverse event rate is similarly high in the control
group, lending further support to this theory. The overall
major adverse event rate was 41.2% for test patients and
36.4% for controls (P .5609). The overall serious adverse
event rate was 61.5% for test patients and 68.2% for con-
trols (P .3761). The device-related adverse event rate was
13.8%. All-cause and aneurysm-related mortality was not
different between the test and control groups.
Endoleaks were the most common adverse event re-
quiring secondary intervention in the Powerlink group.
The vast majority of the endoleaks were of type II and only
3.1% of patients required secondary intervention for treat-
ment of type I endoleak. It is important to note that no type
III endoleaks developed, despite the use of cuffs in 42% of
patients to achieve a proximal seal. There were no type IVendoleaks noted. There have been no reports of late fabric
erosion or defects, as have been reported with other de-
vices. At explantation, no evidence of material fatigue was
appreciated at 24 months.
There was a very low endotension rate noted with this
device, despite its utilization of polytetrafluoroethylene
(PTFE) in its design. The Powerlink does not seem to be
subject to the same transudative phenomenon that was
witnessed with the original Gore Excluder graft, which
prompted a change to a lower-permeability fabric.10
Mean aneurysm diameter and volume were signifi-
cantly reduced at every examination interval from the first
postoperative month up to 60 months. At the 72-month
follow-up interval, themean aneurysm diameter (39.4mm)
and mean aneurysm volume (118 mL) had stabilized and
plateaued. A percentage of patients (82.7%) exhibited a
decrease in aneurysm diameter of 5 mm at 72 months,
while 78.6% of patients exhibited a decrease in volume of
5% at 72 months. These data demonstrate the successful
exclusion of aneurysm sac flow.
There were specific anatomic differences noted be-
tween the test and control groups. The aneurysms in the
test group were significantly smaller than those treated in
the control group. Renal to aortic bifurcation length was
shorter, proximal neck diameter was smaller, and proximal
neck length was longer in the test group. These very
favorable characteristics are a reflection of surgeon compli-
ance to eligibility criteria for the Powerlink graft. In order
to be anatomically suitable for the Powerlink endograft, the
proximal infrarenal neck diameter had to be smaller than 26
mm and the neck length had to be greater than 15mm. The
test group also included patients with “small” aneurysms in
the 4.0 to 5.5 cm range. The excellent long-term results
from this study imply that adherence to anatomic criteria
leads to successful and durable repair. In addition, there
have been numerous reports over the past 5 years positing a
relationship between aneurysm diameter and EVAR suit-
ability and long-term outcome. Ouriel et al published a
study comparing the outcomes in patients undergoing
EVAR who had small (5.5 cm) vs large (5.5 cm) aneu-
rysms.11 While there was no difference in perioperative
mortality between groups, at 24months, the large aneurysm
group had more type I endoleaks, device migration and late
conversion to open surgical repair. These results were similar
to those published by Zarins et al, who cited a higher risk of
rupture, AAA-related death, and surgical conversion in the
large aneurysm subset.12 The EUROpean collaborators on
Stent-graft Techniques for abdominal aortic Aneurysm Re-
pair (EUROSTAR) registry, likewise, demonstrated a
higher aneurysm-relatedmortality, type I endoleak rate and
rate of surgical conversion in the large aneurysm group.13
Taken together, these data imply that patients undergoing
EVAR for large AAA may fare worse than those patients
with small AAA. Patients with larger aneurysms may also
have anatomy that is less amenable to endovascular repair.
Rockman et al demonstrated a higher type I endoleak rate,
shorter neck length, and greater neck tortuosity in the large
aneurysm group.14 Welborn et al performed an anatomic
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longer necks, less neck angulation, longer common iliac
landing zones, and less aortic tortuosity.15 The smaller
aneurysm diameter in the test group in this study thus may
have contributed to the excellent success of endovascular
repair.
In contrast to most other endograft devices, the Pow-
erlink cohort demonstrated a straightening rather than an
angulation of the aortic aneurysm sac over time. This
geometric configuration may prove to be ideal in the avoid-
ance of delayed complications. Harris et al described longi-
tudinal sac foreshortening and subsequent endograft kink-
ing and buckling as a risk factor for graft limb occlusion,
endoleak and disruption of modular graft components.16
Umscheid et al described a mechanism whereby aortic
pulsations exert differential axial stresses on the anterior
and posterior walls of the graft causing anterior angulation
of stent grafts over time and increased risk of endoleak.17
Perhaps the long-body design and seating of the Powerlink
device on the aortic bifurcation prevents foreshortening of
the sac and the potential for endograft buckling or en-
doleak formation. It is clear that the relationship between
aneurysm sac and endograft is a dynamic one, and that
changes in aneurysm sac configuration are inseparable from
translated changes in the endograft device. It would make
intuitive sense that an endograft with enough longitudinal
flexibility and “recoil” to withstand the repetitive forces of
aortic pulsation wouldmaintain a straight-geometrical con-
figuration over time. This in turn would prevent sac short-
ening and the attendant complications of buckling and
kinking. The single-wire woven stent design of the Power-
link serves as a rigid scaffold around which the excluded
aneurysm sac can remodel.
Adverse events that have been observed with other
EVAR devices have not been observed with the Powerlink.
Wire fractures, common in nitinol stent grafts, have not
been observed. The Powerlink employs a cobalt chromium
alloy stent skeleton woven from a single wire. Also, there
has been no fabric erosions related to porosity.
Graft occlusion, which has been reported with other
devices, has been uncommon, affecting 3.7% of patients.
This is less than the 7.2% rate cited in a recent article
assessing predictors for graft limb occlusion.18 Graft limb
occlusions with the Powerlink device have been attributed
to extrinsic compression from underlying iliac disease, ie,
presence of thrombus or plaque, which is why preliminary
angioplasty of the iliac arteries is recommended in this
particular subset of patients. Graft limb occlusions also
seemed to occur in patients with smaller iliac arteries
(11.0 mm), mirroring the results reported by Carrocio et
al.19 Taken together, these data indicate that patient selec-
tion and anatomic evaluation are paramount in considering
utilization of any endograft device. The majority of graft
limb occlusions were able to be treated endovascularly or
locally via thrombectomy rather than with femoral-femoral
crossover or extra-anatomic bypass procedures. When graft
limb thrombosis occurs, thrombolytic therapy is preferredto catheter thromboembolectomy, as balloon catheter ma-
nipulation can be associated with device displacement.
CONCLUSIONS
The Powerlink device appears to be durable and effec-
tive in excluding aneurysm flow and prevention of sac
enlargement over a period of long-term follow-up. The
graft and stent materials have been free from failure and
fatigue. The requirement for only one surgically exposed
femoral artery facilitates graft placement in patients with
limited access routes and reduces the morbidity of an addi-
tional groin wound. The perioperative morbidity and mortal-
ity rate is significantly reduced with Powerlink repair com-
pared with open repair of AAA. The overall survival at 72
months was no different between the two groups, indicating
that the Powerlink system is just as durable in protecting
patients from aneurysm-related death as open repair.
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Distal limb extension 13.3% 25/188
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Volume 48, Number 3 Wang and Carpenter 545.e1Table I, online only. Inclusion and exclusion criteria
Proximal infrarenal neck
15 mm length
60-degree angle
26 mm maximum diameter, 18 mm minimum diameter
AAA 4.0 cm diameter or rapidly growing AAA
Iliac diameter 7 mm on at least one side
Dispensable inferior mesenteric artery
Preservation of at least one hypogastric artery
Iliac seal zone of 1.5 cm
Aortic bifurcation diameter 18 mm
No pregnancy
Candidate for open AAA repair
Serum creatinine level 1.7 mg/dL
Willingness to comply with follow-up schedule
No bleeding disorders
Life expectancy 2 years
No connective tissue disordersTable V, online only. Patient follow-up from 1 to 72 monthsa
Powerlink N  192
1 mo 6 mo 12 mo 24 mo 36 mo 48 mo 60 mo 72 mo
No deviceb 1 1 0 0 0 0 0 0
Conversion to open repairc 3 2 3 2 2 1 0 0
Expired 2 8 13 22 29 34 41 42
Withdrawn/lost to follow-up 0 4 7 16 24 29 36 39
Available 190 180 175 158 148 132 102 43
Clinical examination n (%) 135 (71.1) 127 (70.6) 152 (86.9) 151 (95.6) 143 (96.6) 125 (94.7) 82 (80.4) 33 (76.7)
Site CT imaging n (%) 186 (97.9) 171 (95.0) 157 (89.7) 144 (91.1) 133 (89.9) 111 (84.1) 72 (70.6) 28 (65.1)
Core Lab CT imaging n (%) 123 (64.7) 119 (66.1) 147 (84.0) 142 (89.9) 130 (87.8) 119 (90.2) 90 (88.2) 35 (81.4)
Site KUB imaging n (%) 114 (60.0) 107 (59.4) 136 (77.7) 132 (83.5) 115 (77.7) 101 (76.5) 68 (66.7) 23 (53.5)
Core Lab KUB imaging n (%) 114 (60.0) 107 (59.4) 136 (77.7) 132 (83.5) 115 (77.7) 101 (76.5) 68 (66.7) 23 (53.5)
Site evaluated for endoleak 186 (97.9) 171 (95.0) 157 (89.7) 144 (91.1) 133 (89.9) 111 (84.1) 72 (70.6) 28 (65.1)
Core Lab evaluated for
endoleak 111 (58.4) 101 (56.1) 129 (73.7) 115 (72.9) 103 (69.6) 95 (72.0) 74 (72.5) 28 (65.1)
Site evaluated for aneurysm
enlargement n/a 82 (45.6) 100 (57.1) 102 (64.6) 96 (64.9) 88 (66.7) 59 (57.8) 27 (62.8)
Core Lab evaluated for
aneurysm enlargement n/a 85 (47.2) 102 (58.3) 101 (63.9) 95 (64.1) 89 (67.4) 64 (62.7) 29 (67.4)
aData analysis sample size varies for each of the time points above and in the following tables. This variability is due to patient availability for follow-up, as well
as, quantity and quality of images available. Totals at time points are not cumulative, unless otherwise noted.
bAccess failure; commercially available device implanted.
cThe patients who underwent conversion to open repair are continuing to returnTable III. online only. Devices implanted and
percentage of proximal cuff and distal limb extension
usage
Devices implanted 97.90% 188/192
Bifurcated grafts
28  135-mm 21.3% 40/188
28  155-mm 43.6% 82/188
25  135-mm 13.8% 26/188
25  155-mm 21.3% 40/188
Proximal cuff 42.0% 79/188for follow-up.
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September 2008545.e2 Wang and CarpenterTable IX, online only. Survival estimates and 95% confidence limits through 72 months for Powerlink and control
groups
Treatment group Mo Patients remaining Proportion surviving Lower 95% CL Upper 95% CL
Control 0 66 1 — —
1 62 0.9394 0.8818 0.9970
3 60 0.9240 0.8599 0.9881
6 59 0.9240 0.8599 0.9881
12 53 0.8756 0.7948 0.9564
18 45 0.8591 0.7736 0.9446
24 43 0.8396 0.7479 0.9313
36 38 0.7796 0.6722 0.8870
48 27 — — —
60 13 — — —
72 0 — — —
Powerlink 0 192 1 — —
1 190 0.9896 0.9752 1.0000
3 186 0.9739 0.9514 0.9964
6 180 0.9581 0.9297 0.9865
12 175 0.9421 0.9088 0.9754
18 167 0.9095 0.8683 0.9507
24 164 0.9040 0.8619 0.9461
36 148 0.8758 0.8282 0.9234
48 120 0.8203 0.7637 0.8769
60 74 0.7768 0.7115 0.8421
72 29 0.6965 0.6073 0.7857Table X, online only. AAA related survival estimates and 95% confidence limits through 72 months for Powerlink and
controls
Treatment group Mo Patients remaining Proportion surviving Lower 95% CL Upper 95% CL
Control 0 66 1 — —
1 62 0.9394 0.8818 0.9970
3 60 —a —a —a
6 59 —a —a —a
12 53 —a —a —a
18 45 —a —a —a
24 43 —a —a —a
36 38 —a —a —a
48 29 —a —a —a
60 13 —a —a —a
72 0 —a —a —a
Powerlink 0 192 1 — —
1 190 0.9896 0.9752 1.0000
3 186 0.9896 0.9752 1.0000
6 180 0.9896 0.9752 1.0000
12 175 0.9896 0.9752 1.0000
18 167 0.9787 0.9579 0.9995
24 164 —a —a —a
36 148 —a —a —a
48 120 —a —a —a
60 74 —a —a —a
72 29 —a —a —a
aSince there were no AAA related deaths beyond the 1-month interval for the controls and the 3-month interval for the Powerlink patients, no point estimates
and confidence intervals are provided. It is customary to terminate the Kaplan-Meier curve at the last event.
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Treatment group Mo Patients remaining Proportion free from procedure Lower 95% CL Upper 95% CL
Powerlink 0 192 1.0000 — —
1 187 0.9740 0.9515 0.9965
3 178 0.9477 0.9161 0.9793
6 172 0.9423 0.9092 0.9754
12 163 0.9203 0.8817 0.9589
18 153 0.8918 0.8469 0.9367
24 148 0.8799 0.8327 0.9271
36 131 0.8550 0.8033 0.9067
48 107 0.8484 0.7955 0.9013
60 63 0.8311 0.7741 0.8881
72 22 — — —Table XII, online only. Estimated rates of freedoms from major adverse event through 72 months
Treatment group Mo Patients remaining Proportion free from major AE Lower 95% CL Upper 95% CL
Control 0 66 1 — —
1 52 0.7879 0.6893 0.8865
3 50 0.7724 0.6711 0.8737
6 50 0.7724 0.6711 0.8737
12 44 0.7090 0.5987 0.8193
18 39 0.6764 0.5621 0.7907
24 38 0.6764 0.5621 0.7907
36 33 0.6215 0.5010 0.7420
48a 28 —a —a —a
60a 13 —a —a —a
72a 0 —a —a —a
Powerlink 0 192 1 — —
1 180 0.9375 0.9032 0.9718
3 167 0.8698 0.8222 0.9174
6 160 0.8437 0.7923 0.8951
12 148 0.7907 0.7331 0.8483
18 133 0.8206 0.7567 0.8845
24 126 0.6933 0.6274 0.7592
36 110 0.6480 0.5794 0.7166
48 82 0.5453 0.4722 0.6184
60 47 0.4929 0.4157 0.5701
72 15 0.3969 0.3028 0.4910
aSince there are no events in the control group beyond 31 months, the estimated freedom from MAE and confidence intervals were not extended.
bMajor adverse events include myocardial infarction within 30 days; coronary intervention within 30 days; respiratory failure between 24 hours and 30 days;
aneurysm rupture; kidney failure; additional procedures; conversion to open surgical repair; stroke; or death.Table XIII, online only. Estimated rates of freedom from endoleak through 72 months
Treatment group Mo Patients remaining Proportion free from endoleak Lower 95% CL Upper 95% CL
Powerlink 0 189 1 — —
1 171 0.9048 0.8629 0.9467
3 150 0.8091 0.7530 0.8652
6 142 0.7925 0.7345 0.8505
12 134 0.7698 0.7092 0.8304
18 129 0.7698 0.7092 0.8304
24 126 0.7698 0.7092 0.8304
36 113 0.7635 0.7023 0.8247
48 93 0.7425 0.6786 0.8064
60 60 0.7256 0.6590 0.7922
72 27 0.6991 0.6254 0.7728
